MoH Amends New Drugs & Clinical Trial Rules To Change Definition Of Bioanalytical Laboratory

New Delhi : The Union ministry of health and family welfare has amended the New Drugs and Clinical Trial Rules 2019, bringing in changes in the definition of bioavailability and bioequivalence study centre. A Gazette Notification, imposing the amendment on the rules related to standalone bioanalytical laboratory was published on Tuesday, said the country’s drug regulator.

The amendment, named as the New Drugs and Clinical Trials (Amendment) Rules, brought in a change in the Rule 2, in sub-rule (1) in clause (g) of the Rules 2019, which has come into force from the date of publication in the official gazette.

The relevant rule defines bioavailability and bioequivalence study centre as a centre created or established to undertake bioavailability study or bioequivalence study of a drug for either clinical part or for both clinical and analytical part of such study.

According to the amendment, the words “either clinical part or for both”, the words “either clinical part or analytical part or for both”, shall be substituted. The amendment is to bring in more clarity to the particular rule and the definition.

The Ministry, on February 5, 2021, notified the draft amendment to the rule, inviting objections and suggestions from persons likely to be affected due to the amendment before the expiry of a period of fifteen days from the date on which the copies of official gazette containing the notification were made available to the public.

The Ministry, in its latest notification said that the objections and suggestions received from the public on these rules have been considered by the Central Government.

Following this, the Government with the powers under the Drugs and Cosmetics Act, 1940, after consultation with the Drugs Technical Advisory Board, made the rules through the notification in the Official Gazette.

Earlier in August, the Centre has notified a draft amendment in the Drugs Rules, 1945, to add a provision for deemed approval of license to manufacture drugs for examination, test or analysis, if the authority does not communicate it in seven working days from the date of receipt of application.

  • Related Posts

    • Pharma
    • March 27, 2024
    • 98 views
    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Haryana has blacklisted Maiden Pharmaceuticals Ltd, based at Sonepat, for three years, thereby debarring the firm from participating in state tenders. All rate contracts issued to the firm have also…

    • Pharma
    • March 27, 2024
    • 67 views
    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    New Delhi: The Drugs Consultative Committee (DCC), the advisory committee formed by the Central government to advise the Central and state governments on matters that require uniform implementation of drug laws…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Lee Health develops natural capsule for effective Heart care

    Lee Health develops natural capsule for effective Heart care

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down